Prelude therapeutics incorporated
Biotechnology:-Biological-Products-(No-Diagnostic-Substances)
PRLD
Executive/
Director
Links
Price
- Last Close
-
$ 1.38
$ +0.13 9.96 %
Jan 3, 2025
- 52-Week High/Low
- $6.46 - $1.69
- YTD
- 7.8%
- Trading Volume
- 3,566
- Market Cap Full
- $ 75.7M
- Shares Outstanding
-
54.8M
Oct 27, 2023
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | - | - | - | - | -5% | -44.1% | -41.2% | -5.6% | 10.5% | 7.8% |
| Q2 | - | - | - | - | 4% | -28.4% | -28.7% | -21.1% | -20.7% | - |
| Q3 | - | - | - | - | 8% | 9.2% | 26.6% | -31.3% | -20.6% | - |
| Q4 | - | - | - | - | 137.5% | -60.2% | -8.6% | 54.4% | 24.3% | - |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 7.8% | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | -23.2% | 31.1% | 9.8% | -21.2% | 4% | -4.7% | 75.1% | -20.6% | - | - | - | - |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0% | 0% | 0% | 0% | 0% | 0% | -83% | -51% | -29% | -70% | 8% |
Earnings
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Q1 | -0.47 | -0.63 | -0.58 |
| Q2 | -0.58 | -0.58 | -0.54 |
| Q3 | -0.66 | -0.63 | -0.45 |
| Q4 | -0.72 | -0.60 | - |
| A | -2.4 | -2.4 | -1.57 |
Annual Returns
52 Week
High/Low
Annual
Earnings
Chart
Trading Volume
Outstanding Shares
(In Millions) +
Jan 16, 2024
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Mar | - | 46.6 | 47.6 | 47.9 |
| Jun | - | 47 | 47.7 | 48 |
| Sep | - | 47.1 | 47.8 | - |
| Dec | 43.7 | 47.2 | 47.9 | 54.8 |
SEC Filings
Financial Ratios
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Asset Management | |||||
| Inventory / Stock Turnover | - | - | - | - | - |
| Fixed Asset Turnover | - | - | - | - | - |
| Total Asset Turnover | - | - | - | - | - |
| Leverage | |||||
| Debt Ratio | - | - | - | - | - |
| Debt – Equity Ratio | - | - | - | - | - |
| Interest Coverage | 13.8 | 57 | 29.5 | - | - |
| Equity multiplier | 0.1 | - | - | 0.1 | - |